In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on
99mTc-sestamibi SPECT/CT
Renal tumour/in situ metabolomics
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
accepted:
03
11
2020
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Definite noninvasive characterisation of renal tumours positive on To investigate whether combined A tissue microarray analysis of 33 tumour samples from 28 patients was used to investigate whether their in situ metabolomic status correlates with their features on MALDI MSI data analysis and image generation were facilitated by FlexImaging v. 4.2, while k-means analysis by SCiLS Lab software followed by R-package CARRoT analysis was used for assessing the highest predictive power in the differential of RO versus chRCC. Heatmap-based clustering, sparse partial least-squares discriminant analysis, and volcano plots were created with MetaboAnalyst 3.0. We identified a discriminatory metabolomic signature for The current study expands the spectrum of For preoperative evaluation of solid renal tumours,
Sections du résumé
BACKGROUND
BACKGROUND
Definite noninvasive characterisation of renal tumours positive on
OBJECTIVE
OBJECTIVE
To investigate whether combined
DESIGN SETTING AND PARTICIPANTS
METHODS
A tissue microarray analysis of 33 tumour samples from 28 patients was used to investigate whether their in situ metabolomic status correlates with their features on
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
METHODS
MALDI MSI data analysis and image generation were facilitated by FlexImaging v. 4.2, while k-means analysis by SCiLS Lab software followed by R-package CARRoT analysis was used for assessing the highest predictive power in the differential of RO versus chRCC. Heatmap-based clustering, sparse partial least-squares discriminant analysis, and volcano plots were created with MetaboAnalyst 3.0.
RESULTS AND LIMITATIONS
CONCLUSIONS
We identified a discriminatory metabolomic signature for
CONCLUSIONS
CONCLUSIONS
The current study expands the spectrum of
PATIENT SUMMARY
RESULTS
For preoperative evaluation of solid renal tumours,
Identifiants
pubmed: 34337482
doi: 10.1016/j.euros.2020.11.001
pii: S2666-1683(20)36364-3
pmc: PMC8317898
doi:
Types de publication
Journal Article
Langues
eng
Pagination
88-96Informations de copyright
© 2020 The Authors.
Références
Int J Cancer. 2019 Jul 15;145(2):484-493
pubmed: 30628065
Clin Cancer Res. 2016 Dec 15;22(24):6236-6246
pubmed: 27256309
Am J Surg Pathol. 2016 Jul;40(7):865-75
pubmed: 26900816
EJNMMI Res. 2017 Dec;7(1):29
pubmed: 28357787
Histopathology. 2019 Aug;75(2):174-184
pubmed: 30895640
EJNMMI Res. 2017 Dec;7(1):34
pubmed: 28405927
Hum Pathol. 2017 May;63:149-156
pubmed: 28315424
BJU Int. 2017 May;119(5):661-666
pubmed: 28058773
EJNMMI Res. 2017 Oct 2;7(1):80
pubmed: 28971329
Expert Rev Proteomics. 2016 Dec;13(12):1103-1120
pubmed: 27748142
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W652-60
pubmed: 19429898
Eur Urol. 2016 Mar;69(3):413-6
pubmed: 26386607
J Nucl Med Technol. 2019 Sep;47(3):258-262
pubmed: 31019039
Anticancer Res. 2014 May;34(5):2255-61
pubmed: 24778028
Virchows Arch. 2010 Apr;456(4):355-65
pubmed: 20300772
Histochem Cell Biol. 2015 Aug;144(2):147-56
pubmed: 25929744
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Cell Rep. 2018 Apr 3;23(1):255-269.e4
pubmed: 29617665
Cell Rep. 2018 Jun 19;23(12):3698
pubmed: 29925010
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Virchows Arch. 2018 Dec;473(6):725-738
pubmed: 30232607
Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6
pubmed: 17202168
J Pathol. 2015 Sep;237(1):123-32
pubmed: 25965788
Metabolites. 2019 Jul 24;9(8):
pubmed: 31344778
J Pathol. 2015 Jan;235(1):3-13
pubmed: 25201776
Am J Surg Pathol. 2014 Dec;38(12):1588-602
pubmed: 25025441
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282
pubmed: 29891694
Oncol Lett. 2020 Apr;19(4):3316-3332
pubmed: 32256826
Mod Pathol. 2019 Nov;32(11):1698-1707
pubmed: 31231128
Nat Protoc. 2016 Aug;11(8):1428-43
pubmed: 27414759
Kidney Cancer. 2017 Jul 26;1(1):3-13
pubmed: 30334000
Eur Urol Focus. 2019 Jul;5(4):608-618
pubmed: 29452772